Search Results

You are looking at 1 - 10 of 41 items for :

  • "advanced glycation end products" x
  • All content x
Clear All
Free access

Gemma Llauradó, Victòria Ceperuelo-Mallafré, Carme Vilardell, Rafael Simó, Pilar Gil, Albert Cano, Joan Vendrell, and José-Miguel González-Clemente

Scuteri A deGroof RC Lakatta EG 2001 Improved arterial compliance by a novel advanced glycation end-product crosslink breaker . Circulation 104 1464 – 1470 . ( doi:10.1161/hc3801.097806 ) Komosinska-Vassev K Olczyk P Winsz-Szczotka K

Free access

M Alves, D Andrade Cunha, V Cristine Calegari, M J A Saad, A Carlos Boschero, L Augusto Velloso, and E Melani Rocha

( Carvalho et al. 1996 , Rocha et al. 2003 ) and the formation of advanced glycation end products (AGEs), as also observed in other tissues ( Vlassara et al. 1994 , Stitt 2001 ). Taken together, these two hypotheses may predict that metabolic events

Free access

M Alves, D Andrade Cunha, V Cristine Calegari, M J A Saad, A Carlos Boschero, L Augusto Velloso, and E Melani Rocha

of Figure 1A, 2A and 3A which were also published as Figure 3a, 3c and 3e in Alves M, Calegari VC, Cunha DA, Saad MJA, Velloso LA & Rocha EM (2005) Increased expression of advanced glycation end-products and their receptor, and activation of nuclear

Free access

Sheng-Gao Tang, Xiao-Yu Liu, Ji-Ming Ye, Ting-Ting Hu, Ying-Ying Yang, Ting Han, and Wen Tan

and AGEs levels were measured in plasma from every sample by commercially available RATTNF-α, IL-6 and INSULIN ELISA kits (JissKang Biotech, Qingdao, China) and RAT Advanced Glycation End Products ELISA kit (SenBeiJia Biological, Nanjing, China

Free access

Jian-Ting Ke, Mi Li, Shi-Qing Xu, Wen-Jian Zhang, Yong-Wei Jiang, Lan-yun Cheng, Li Chen, Jin-Ning Lou, and Wei Wu

of glomerular microvascular lesions, though the underlying mechanism responsible for the development of these lesions remains elusive. Advanced glycation end products (AGEs) have been found to be a major cause of diabetic microvascular lesions. AGEs

Free access

Antonios Chatzigeorgiou, Eleni Kandaraki, Christina Piperi, Sarantis Livadas, Athanasios G Papavassiliou, Michael Koutsilieris, Apostolos Papalois, and Evanthia Diamanti-Kandarakis

Introduction Advanced glycation end products (AGEs) are a heterogeneous group of cross-linking molecules, formed from a non-enzymatic reaction of reducing sugars with the amino groups of proteins and lipids via the Maillard reaction. AGEs are highly

Restricted access

Michal Silber, Irit Miller, Hadas Bar-Joseph, Ido Ben-Ami, and Ruth Shalgi

to hyperglycemia, which induces an accelerated production of advanced glycation end-products (AGEs; Friedman 1999 ), and an upregulation of their receptor, RAGE ( Yao & Brownlee 2010 ). Accordingly, the levels of AGEs and RAGE were found to be

Free access

Janine Leckelt, Pedro Guimarães, Annett Kott, Alfredo Ruggeri, Oliver Stachs, and Simone Baltrusch

(Tarrytown, NY, USA). Serum samples were assayed to quantify C-peptide values and advanced glycation end product (AGE) levels (mouse C-peptide and mouse AGE ELISA; ALPCO Diagnostics, Salem, NH, USA). In vivo corneal confocal microscopy Initially and

Free access

Diane Donegan, Laurie K Bale, and Cheryl A Conover

(TGF)-β, IGF1 and IGF2 were purchased from R&D Systems. Reagents for SDS-PAGE, mini-gels and blocking buffer were purchased from Bio-Rad Laboratories. Mannitol and d -glucose were purchased from Sigma-Aldrich. Advanced glycation end products (AGE), AGE

Free access

Yan Ding and Mary E Choi

. Hyperglycemia-mediated alterations of intracellular metabolism, including the accumulation of advanced glycation end-products (AGEs), activation of protein kinase C (PKC), and oxidative stress are the major contributing factors to the pathogenesis of DN